Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 1(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT03401073Phase 2Completed

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

Role: collaborator

NCT02483845Phase 1Unknown

Natalizumab in Inclusion Body Myositis (IBM)

Role: lead

NCT01637064Unknown

Dermatomyositis and Polymyositis Registry

Role: lead

NCT01835782Phase 1Unknown

Determining the Safety of L-serine in ALS

Role: lead

NCT00919555Phase 1Completed

Combination Therapy in Amyotrophic Lateral Sclerosis (ALS)

Role: lead

NCT01259050Phase 1Completed

Safety Study of High Doses of Zinc in ALS Patients

Role: lead

NCT00917956Completed

Lithium in Inclusion Body Myositis (IBM)

Role: lead

NCT01020331Phase 2Completed

Memantine Therapy in Amyotrophic Lateral Sclerosis

Role: lead

All 8 trials loaded